ERBB2 and breast carcinoma: Notably, T-DM1 and DS8201 have received FDA approval for managing HER2-positive breast cancer, as supported by the results of the EMILIA, KATHERINE, and DESTINY-Breast01 clinical trials (11, 24, 25).